MedPath

NATACYN

NATACYN (natamycin ophthalmic suspension) 5% Sterile

Approved
Approval ID

2818fcb8-5bac-41fb-864e-3b598308a428

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 9, 2023

Manufacturers
FDA

Eyevance Pharmaceuticals, LLC

DUNS: 080876046

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

natamycin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code71776-005
Application NumberNDA050514
Product Classification
M
Marketing Category
C73594
G
Generic Name
natamycin
Product Specifications
Route of AdministrationOPHTHALMIC
Effective DateOctober 9, 2023
FDA Product Classification

INGREDIENTS (5)

SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
BENZALKONIUM CHLORIDEInactive
Code: F5UM2KM3W7
Classification: IACT
NATAMYCINActive
Quantity: 50 mg in 1 mL
Code: 8O0C852CPO
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

NATACYN - FDA Drug Approval Details